Beat to Beat A Study in Paediatric, Adolescent and Young Adult Patients Who Are Undergoing or Have Undergone Cancer Therapy to Evaluate the Agreement Between QTc Measured Using 12 Lead Electrocardiogram (ECG) and a Wearable Device ECG
Neoplasms, Cardiac Arrhythmia
About this trial
This is an interventional diagnostic trial for Neoplasms focused on measuring QT prolongation, cancer, paediatric, ECG application, 12 lead ECG
Eligibility Criteria
Inclusion Criteria: Paediatric or adolescent diagnosis of cancer AND an inpatient of The Royal Children's Hospital, Melbourne for at least 5 days at the time of consent. Patient age ≥ 7 years at time of eligibility screening If age < 18 years, parent or guardian able to provide consent Parental or participant ( if > 18 years of age) possession of the following at time of eligibility screening, ascertained from automatic hardware/software/device pairing check: iPhone (6s or later) with iOS version 15.0 or later defined as iPhone model/iOS version used to complete screening eligibility. Proficient in written and spoken English, defined by self-report of comfort reading, writing, and speaking English on iPhone. Valid phone number associated with iPhone, ascertained from self-report. Valid email address, ascertained from self-report. Participants or parents need to be able to press down on the wearable device crown for 30 seconds Exclusion Criteria: Unable to wear the wearable device. < 18 years of age without guardian or parent to provide consent. Interpreter required for consent purposes.
Sites / Locations
- The Royal Children's HospitalRecruiting
Arms of the Study
Arm 1
Experimental
ECG App arm
Participants will be provided with a wearable device on Day 1 and Day 4 whilst admitted in hospital.